Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lianhua Jizhi Pian is an investigational Traditional Chinese Medicine (TCM) developed by Shijiazhuang Yiling Pharmaceutical for the treatment of acute tracheobronchitis. Classified as a Category 1.1 innovative TCM in China, it is specifically indicated for the 'phlegm-heat' syndrome, which presents with symptoms such as cough, yellow sputum, and chest congestion. The drug is part of the 'Lianhua' respiratory product line and is formulated as an oral tablet. It aims to provide therapeutic benefits through anti-inflammatory, antitussive, and expectorant actions. As of 2024, Lianhua Jizhi Pian is in Phase 2 clinical development, following the success of other respiratory products from the same developer like Lianhua Qingwen and Lianhua Qingke.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lianhua Jizhi Pian.